ReviewTrends in immunology2022
Fate-mapping mice: new tools and technology for immune discovery.
Review in Trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A common progenitor gives rise to fibroblastic reticular cells and vascular smooth muscle cells in murine lymph nodes.The Journal of experimental medicine · 2026Article
- Aberrant T follicular helper cells generated by TNature immunology · 2025Article
- New insights into muscularis macrophages in the gut: from their origin to therapeutic targeting.Immunologic research · 2023Review
- Crosstalk between gut microbiota and gut resident macrophages in inflammatory bowel disease.Journal of translational internal medicine · 2023Article
- Group 2 Innate Lymphoid Cells Protect Mice from Abdominal Aortic Aneurysm Formation via IL5 and Eosinophils.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Cre-loxP-mediated genetic lineage tracing: Unraveling cell fate and origin in the developing heart.Frontiers in cardiovascular medicine · 2023Review
- Macrophage Fate Mapping.Current protocols · 2022Article
- Divide and Conquer: Phenotypic and Temporal Heterogeneity Within CD8Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The fate-mapping mouse has become an essential tool in the immunologist's toolbox. Although traditionally used by developmental biologists to trace the origins of cells, immunologists are turning to fate-mapping to better understand the development and function of immune cells. Thus, an expansion in the variety of fate-mapping mouse models has occurred to answer fundamental questions about the immune system. These models are also being combined with new genetic tools to study cancer, infection, and autoimmunity. In this review, we summarize different types of fate-mapping mice and describe emerging technologies that might allow immunologists to leverage this valuable tool and expand our functional knowledge of the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.